ID   EPHA7_HUMAN             Reviewed;         998 AA.
AC   Q15375; A0AUX7; B2R8W1; B7ZLJ9; B7ZLK0; Q59G40; Q5VTU0; Q8N368; Q9H124;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2007, sequence version 3.
DT   12-OCT-2022, entry version 221.
DE   RecName: Full=Ephrin type-A receptor 7;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH homology kinase 3;
DE            Short=EHK-3;
DE   AltName: Full=EPH-like kinase 11;
DE            Short=EK11;
DE            Short=hEK11;
DE   Flags: Precursor;
GN   Name=EPHA7; Synonyms=EHK3, HEK11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=7898931;
RA   Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R.,
RA   Welcher A.A.;
RT   "cDNA cloning and tissue distribution of five human EPH-like receptor
RT   protein-tyrosine kinases.";
RL   Oncogene 10:897-905(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4), AND
RP   VARIANT VAL-138.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [8]
RP   FUNCTION IN MAP2K1; MAP2K2; MAPK1 AND MAPK3 PHOSPHORYLATION.
RX   PubMed=17726105; DOI=10.1073/pnas.0703211104;
RA   Nakanishi H., Nakamura T., Canaani E., Croce C.M.;
RT   "ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation
RT   in human acute leukemias.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:14442-14447(2007).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORM 5).
RX   PubMed=20126984;
RA   Tsuboi M., Mori H., Bunai T., Kageyama S., Suzuki M., Okudela K.,
RA   Takamochi K., Ogawa H., Niwa H., Shinmura K., Sugimura H.;
RT   "Secreted form of EphA7 in lung cancer.";
RL   Int. J. Oncol. 36:635-640(2010).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 32-204.
RA   Walker J.R., Yermekbayeva L., Seitova A., Kania J., Bountra C., Weigelt J.,
RA   Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.;
RT   "Ephrin A7 ligand binding domain.";
RL   Submitted (JUN-2010) to the PDB data bank.
RN   [11]
RP   VARIANT [LARGE SCALE ANALYSIS] TRP-371.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-138; LYS-170; ARG-232; SER-278 AND
RP   SER-903.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI-
CC       anchored ephrin-A family ligands residing on adjacent cells, leading to
CC       contact-dependent bidirectional signaling into neighboring cells. The
CC       signaling pathway downstream of the receptor is referred to as forward
CC       signaling while the signaling pathway downstream of the ephrin ligand
CC       is referred to as reverse signaling. Among GPI-anchored ephrin-A
CC       ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their
CC       interaction regulates brain development modulating cell-cell adhesion
CC       and repulsion. Has a repellent activity on axons and is for instance
CC       involved in the guidance of corticothalamic axons and in the proper
CC       topographic mapping of retinal axons to the colliculus. May also
CC       regulate brain development through a caspase(CASP3)-dependent
CC       proapoptotic activity. Forward signaling may result in activation of
CC       components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1
CC       and MAPK3 which are phosphorylated upon activation of EPHA7.
CC       {ECO:0000269|PubMed:17726105}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer
CC       is composed of an ephrin dimer and a receptor dimer. Oligomerization is
CC       probably required to induce biological responses (By similarity).
CC       Interacts (via PDZ-binding motif) with GRIP1 and PICK1 (via PDZ domain)
CC       (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q15375; P07333: CSF1R; NbExp=2; IntAct=EBI-1383428, EBI-2835440;
CC       Q15375; P29317: EPHA2; NbExp=6; IntAct=EBI-1383428, EBI-702104;
CC       Q15375; P29320: EPHA3; NbExp=2; IntAct=EBI-1383428, EBI-1641575;
CC       Q15375; P29323: EPHB2; NbExp=2; IntAct=EBI-1383428, EBI-1059294;
CC       Q15375; P54760: EPHB4; NbExp=3; IntAct=EBI-1383428, EBI-702121;
CC       Q15375; Q16288: NTRK3; NbExp=2; IntAct=EBI-1383428, EBI-3936704;
CC       Q15375; P52793: Efna1; Xeno; NbExp=2; IntAct=EBI-1383428, EBI-5241529;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I
CC       membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=EPHA7-FL;
CC         IsoId=Q15375-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15375-2; Sequence=VSP_014382;
CC       Name=3;
CC         IsoId=Q15375-3; Sequence=VSP_014380, VSP_014381;
CC       Name=4;
CC         IsoId=Q15375-4; Sequence=VSP_041945;
CC       Name=5; Synonyms=EPHA7-S;
CC         IsoId=Q15375-5; Sequence=VSP_041943, VSP_041944;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing donor splice
CC       site. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Expressed in lung cancer cells, lacks the
CC       kinase domain and is most probably secreted. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92506.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA7ID40466ch6q16.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L36642; AAA74243.1; -; mRNA.
DR   EMBL; AK313529; BAG36308.1; -; mRNA.
DR   EMBL; AB209269; BAD92506.1; ALT_INIT; mRNA.
DR   EMBL; AL121966; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354857; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591036; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48518.1; -; Genomic_DNA.
DR   EMBL; BC027940; AAH27940.1; -; mRNA.
DR   EMBL; BC126125; AAI26126.1; -; mRNA.
DR   EMBL; BC126151; AAI26152.1; -; mRNA.
DR   EMBL; BC143857; AAI43858.1; -; mRNA.
DR   EMBL; BC143858; AAI43859.1; -; mRNA.
DR   CCDS; CCDS5031.1; -. [Q15375-1]
DR   CCDS; CCDS75494.1; -. [Q15375-3]
DR   PIR; I58351; I58351.
DR   RefSeq; NP_001275558.1; NM_001288629.1. [Q15375-2]
DR   RefSeq; NP_001275559.1; NM_001288630.1. [Q15375-3]
DR   RefSeq; NP_004431.1; NM_004440.3. [Q15375-1]
DR   RefSeq; XP_005248726.1; XM_005248669.2.
DR   PDB; 2REI; X-ray; 1.60 A; A=590-899.
DR   PDB; 3DKO; X-ray; 2.00 A; A=590-899.
DR   PDB; 3H8M; X-ray; 2.10 A; A/B=919-990.
DR   PDB; 3NRU; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L=32-204.
DR   PDB; 7EEC; X-ray; 3.10 A; A=599-899.
DR   PDB; 7EED; X-ray; 3.05 A; A=599-899.
DR   PDB; 7EEF; X-ray; 2.60 A; A=599-899.
DR   PDBsum; 2REI; -.
DR   PDBsum; 3DKO; -.
DR   PDBsum; 3H8M; -.
DR   PDBsum; 3NRU; -.
DR   PDBsum; 7EEC; -.
DR   PDBsum; 7EED; -.
DR   PDBsum; 7EEF; -.
DR   AlphaFoldDB; Q15375; -.
DR   SMR; Q15375; -.
DR   BioGRID; 108359; 160.
DR   IntAct; Q15375; 172.
DR   MINT; Q15375; -.
DR   STRING; 9606.ENSP00000358309; -.
DR   BindingDB; Q15375; -.
DR   ChEMBL; CHEMBL4602; -.
DR   DrugBank; DB07970; 5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q15375; -.
DR   GuidetoPHARMACOLOGY; 1827; -.
DR   GlyGen; Q15375; 5 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q15375; -.
DR   PhosphoSitePlus; Q15375; -.
DR   SwissPalm; Q15375; -.
DR   BioMuta; EPHA7; -.
DR   DMDM; 146345416; -.
DR   CPTAC; CPTAC-1783; -.
DR   CPTAC; CPTAC-2787; -.
DR   EPD; Q15375; -.
DR   jPOST; Q15375; -.
DR   MassIVE; Q15375; -.
DR   MaxQB; Q15375; -.
DR   PaxDb; Q15375; -.
DR   PeptideAtlas; Q15375; -.
DR   PRIDE; Q15375; -.
DR   ProteomicsDB; 60549; -. [Q15375-1]
DR   ProteomicsDB; 60550; -. [Q15375-2]
DR   ProteomicsDB; 60551; -. [Q15375-3]
DR   ProteomicsDB; 60552; -. [Q15375-4]
DR   ProteomicsDB; 60553; -. [Q15375-5]
DR   Antibodypedia; 642; 557 antibodies from 36 providers.
DR   DNASU; 2045; -.
DR   Ensembl; ENST00000369297.1; ENSP00000358303.1; ENSG00000135333.15. [Q15375-3]
DR   Ensembl; ENST00000369303.9; ENSP00000358309.4; ENSG00000135333.15. [Q15375-1]
DR   Ensembl; ENST00000680224.1; ENSP00000506130.1; ENSG00000135333.15. [Q15375-4]
DR   GeneID; 2045; -.
DR   KEGG; hsa:2045; -.
DR   MANE-Select; ENST00000369303.9; ENSP00000358309.4; NM_004440.4; NP_004431.1.
DR   UCSC; uc003poe.5; human. [Q15375-1]
DR   CTD; 2045; -.
DR   DisGeNET; 2045; -.
DR   GeneCards; EPHA7; -.
DR   HGNC; HGNC:3390; EPHA7.
DR   HPA; ENSG00000135333; Group enriched (intestine, parathyroid gland).
DR   MIM; 602190; gene.
DR   neXtProt; NX_Q15375; -.
DR   OpenTargets; ENSG00000135333; -.
DR   PharmGKB; PA27822; -.
DR   VEuPathDB; HostDB:ENSG00000135333; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000160189; -.
DR   HOGENOM; CLU_000288_141_0_1; -.
DR   InParanoid; Q15375; -.
DR   OMA; ETDYNTG; -.
DR   OrthoDB; 1585262at2759; -.
DR   PhylomeDB; Q15375; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q15375; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; Q15375; -.
DR   SIGNOR; Q15375; -.
DR   BioGRID-ORCS; 2045; 14 hits in 1106 CRISPR screens.
DR   ChiTaRS; EPHA7; human.
DR   EvolutionaryTrace; Q15375; -.
DR   GeneWiki; EPHA7; -.
DR   GenomeRNAi; 2045; -.
DR   Pharos; Q15375; Tchem.
DR   PRO; PR:Q15375; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q15375; protein.
DR   Bgee; ENSG00000135333; Expressed in cortical plate and 129 other tissues.
DR   Genevisible; Q15375; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099061; C:integral component of postsynaptic density membrane; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; ISS:UniProtKB.
DR   GO; GO:0045499; F:chemorepellent activity; ISS:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0019838; F:growth factor binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007420; P:brain development; ISS:UniProtKB.
DR   GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0050919; P:negative chemotaxis; ISS:UniProtKB.
DR   GO; GO:0048671; P:negative regulation of collateral sprouting; IEA:Ensembl.
DR   GO; GO:0051964; P:negative regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0072178; P:nephric duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0016310; P:phosphorylation; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; ISS:UniProtKB.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl.
DR   GO; GO:0031952; P:regulation of protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10485; EphR_LBD_A7; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034283; EphA7_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane;
KW   Developmental protein; Glycoprotein; Kinase; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   CHAIN           28..998
FT                   /note="Ephrin type-A receptor 7"
FT                   /id="PRO_0000016818"
FT   TOPO_DOM        28..555
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        556..576
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        577..998
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          32..210
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          331..441
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          442..537
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          633..894
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          923..987
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   MOTIF           996..998
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        758
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         639..647
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         665
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         608
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         614
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         791
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         940
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        343
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        410
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         278..279
FT                   /note="PC -> RK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014380"
FT   VAR_SEQ         280..998
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014381"
FT   VAR_SEQ         442..450
FT                   /note="APSQVSGVM -> GMFCVYLH (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041943"
FT   VAR_SEQ         451..998
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041944"
FT   VAR_SEQ         540..544
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|Ref.3"
FT                   /id="VSP_014382"
FT   VAR_SEQ         600..604
FT                   /note="FKFPG -> C (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041945"
FT   VARIANT         138
FT                   /note="I -> V (in dbSNP:rs2278107)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_022105"
FT   VARIANT         170
FT                   /note="E -> K (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042150"
FT   VARIANT         232
FT                   /note="G -> R (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042151"
FT   VARIANT         278
FT                   /note="P -> S (in dbSNP:rs2278106)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_022106"
FT   VARIANT         371
FT                   /note="R -> W (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs371089003)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036090"
FT   VARIANT         903
FT                   /note="P -> S (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042152"
FT   STRAND          33..37
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          48..51
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          54..61
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          67..74
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          78..80
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          83..86
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          96..106
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   TURN            109..111
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          121..132
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   HELIX           140..142
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          144..150
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          168..174
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          178..190
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   STRAND          192..202
FT                   /evidence="ECO:0007829|PDB:3NRU"
FT   HELIX           611..613
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          614..616
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           617..624
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           630..632
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          633..641
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          643..652
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          655..657
FT                   /evidence="ECO:0007829|PDB:3DKO"
FT   STRAND          660..666
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           673..686
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          697..701
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          703..705
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          708..712
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           719..725
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   TURN            726..728
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           732..751
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           761..763
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          764..766
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   STRAND          772..774
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           800..802
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           805..810
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           815..830
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   TURN            836..839
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           842..850
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           863..872
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           877..879
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           883..895
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           897..899
FT                   /evidence="ECO:0007829|PDB:2REI"
FT   HELIX           928..934
FT                   /evidence="ECO:0007829|PDB:3H8M"
FT   HELIX           938..940
FT                   /evidence="ECO:0007829|PDB:3H8M"
FT   HELIX           941..946
FT                   /evidence="ECO:0007829|PDB:3H8M"
FT   HELIX           952..956
FT                   /evidence="ECO:0007829|PDB:3H8M"
FT   HELIX           960..965
FT                   /evidence="ECO:0007829|PDB:3H8M"
FT   HELIX           971..988
FT                   /evidence="ECO:0007829|PDB:3H8M"
FT   CONFLICT        Q15375-3:278
FT                   /note="R -> C (in Ref. 6; AAH27940)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   998 AA;  112097 MW;  479B9CA0D2BB06EB CRC64;
     MVFQTRYPSW IILCYIWLLR FAHTGEAQAA KEVLLLDSKA QQTELEWISS PPNGWEEISG
     LDENYTPIRT YQVCQVMEPN QNNWLRTNWI SKGNAQRIFV ELKFTLRDCN SLPGVLGTCK
     ETFNLYYYET DYDTGRNIRE NLYVKIDTIA ADESFTQGDL GERKMKLNTE VREIGPLSKK
     GFYLAFQDVG ACIALVSVKV YYKKCWSIIE NLAIFPDTVT GSEFSSLVEV RGTCVSSAEE
     EAENAPRMHC SAEGEWLVPI GKCICKAGYQ QKGDTCEPCG RGFYKSSSQD LQCSRCPTHS
     FSDKEGSSRC ECEDGYYRAP SDPPYVACTR PPSAPQNLIF NINQTTVSLE WSPPADNGGR
     NDVTYRILCK RCSWEQGECV PCGSNIGYMP QQTGLEDNYV TVMDLLAHAN YTFEVEAVNG
     VSDLSRSQRL FAAVSITTGQ AAPSQVSGVM KERVLQRSVE LSWQEPEHPN GVITEYEIKY
     YEKDQRERTY STVKTKSTSA SINNLKPGTV YVFQIRAFTA AGYGNYSPRL DVATLEEATG
     KMFEATAVSS EQNPVIIIAV VAVAGTIILV FMVFGFIIGR RHCGYSKADQ EGDEELYFHF
     KFPGTKTYID PETYEDPNRA VHQFAKELDA SCIKIERVIG AGEFGEVCSG RLKLPGKRDV
     AVAIKTLKVG YTEKQRRDFL CEASIMGQFD HPNVVHLEGV VTRGKPVMIV IEFMENGALD
     AFLRKHDGQF TVIQLVGMLR GIAAGMRYLA DMGYVHRDLA ARNILVNSNL VCKVSDFGLS
     RVIEDDPEAV YTTTGGKIPV RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM
     SNQDVIKAIE EGYRLPAPMD CPAGLHQLML DCWQKERAER PKFEQIVGIL DKMIRNPNSL
     KTPLGTCSRP ISPLLDQNTP DFTTFCSVGE WLQAIKMERY KDNFTAAGYN SLESVARMTI
     EDVMSLGITL VGHQKKIMSS IQTMRAQMLH LHGTGIQV
//
